

Thank you for joining the webinar!

We are admitting audience members from the waiting room.

Please allow a few moments for the webinar to begin.



HEALEY ALS Platform Trial

Community Q&A – December 19, 2024



Healey & AMG Center

Sean M. Healey & AMG Center for ALS
at Massachusetts General Hospital



The AMG Foundation



WORKING

AS A

TEAM



This trial is **dedicated to all people living with ALS**, their families, and friends. Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS

This breakthrough trial would not be possible without your participation.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

Thank You

Partnership, progress, and the pathway forward




Common protocol and shared infrastructure allow for operational and scientific efficiencies

Summary of 2024 Study Activities:


- **559** participants enrolled in Regimens F and G
 - Enrollment timelines were met, and databases have been locked
- Over **150,000** samples collected
 - This includes whole blood, plasma, serum, urine, cerebrospinal fluid (CSF)
- **872** site staff working on the trial

The HEALEY ALS Platform Trial is designed to provide decisive answers and direction with efficient execution

HEALEY ALS Platform Trial



The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug



Primary Endpoint (Placebo-Controlled Period)

Change from baseline in disease severity as measured by the ALSFRS-R total score and survival

Safety, Secondary, and Exploratory Endpoints

(respiratory function, survival, biomarkers + regimen-specific endpoints)

Platform trials are a unique opportunity to advance science



DNA – whole genome sequencing



Neurofilaments –for all regimens




Biomarkers (Blood, CSF) – several drug-specific biomarkers



Speech Analysis – emerging digital biomarker




Home Spirometry – critical during the pandemic



Additional biomarkers/outcome measures for upcoming regimens (new patient-reported outcomes; PBMCs for stem cell generation)

The HEALEY ALS Platform Trial operates across an expanding network of coordinated sites nationwide



**74 Sites Activated for
Regimens F and G**

Site Map & Contacts:



<https://bit.ly/3g2NZr5>



NEALS

Northeast Amyotrophic
Lateral Sclerosis
Consortium®

The HEALEY ALS Platform Trial is a perpetual, adaptive trial

NEWS · 5 MINUTE READ · DEC | 12 | 2024

Sean M. Healey & AMG Center Announces Updates to HEALEY ALS Platform Trial Master Protocol

View Press Release:



<https://bit.ly/4iKxSNO>

- The duration of the Randomized Controlled Trial (RCT) period is **extended from 24 to 36 weeks**
- The inclusion criteria were modified, with the **time since symptom onset now set at 24 months**
- The visit schedule has been made more streamlined and flexible, offering **increased opportunities for remote visits** in the Active Treatment Extension (ATE)
- Addition of **peripheral blood mononuclear cell (PBMC) collection**, which will be banked for future generation of induced pluripotent stem cells (iPSCs)
- **Thank you to our Patient Advisory Committee for invaluable feedback**

HEALEY ALS Platform Trial News

NEWS · 5 MINUTE READ · JUL | 15 | 2024

Healey & AMG Center for ALS Announces
New Investigational Drug Monepantel from
PharmAust Limited will begin design for
inclusion in HEALEY ALS Platform Trial

*“We are thrilled to work with PharmAust leadership
to design their regimen to investigate Monepantel for
people with ALS.”*

Merit Cudkowicz, MD, MSc

Director, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital

* PharmAust is now Neurizon Therapeutics

View Press Release:



<https://bit.ly/3zWwm9C>

- Drug candidates for the Platform Trial are chosen by a group of expert ALS scientists (the Therapy Evaluation Committee) and members of the Healey & AMG Center Science Advisory Committee
- Industry partners from selected companies work with the Healey Center Trial Design Team, the Northeast ALS Consortium (NEALS), Barrow Neurological Institute and Berry Consultants to tailor a new regimen to their investigational product

Acceleration Centers of Enrollment (ACE) Initiative

NEWS · 5 MINUTE READ · SEP | 4 | 2024

Sean M. Healey & AMG Center, Never Surrender, Inc. Establish Acceleration Center of Enrollment at University of Minnesota

View Press Release:



<https://bit.ly/3BhIYKg>

- The initiative will be led by a team of clinical investigators from **Mass General, Northwestern** and the **University of Minnesota**.
- Support for the ACE Initiative comes from an anonymous donor, ALS ONE, the Les Turner ALS Foundation, and Never Surrender.

NEWS · 5 MINUTE READ · AUG | 20 | 2024

Sean M. Healey & AMG Center for ALS and Les Turner ALS Center at Northwestern Medicine Establish Acceleration Centers of Enrollment Initiative

“By funding staff, training, and infrastructure, ACE is a vital step towards faster, more efficient research and ultimately, finding treatments and a cure for ALS.”

Jennifer DiMartino

Executive Director of ALS ONE


Sharing our experience

Research publications available via open access

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

First published: 21 December 2021

Open Access




<https://onlinelibrary.wiley.com/doi/10.1002/ana.26285>

Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis

First published: 28 May 2023

Open Access



<https://onlinelibrary.wiley.com/doi/10.1002/ana.26714>

New and Upcoming Publications

Not yet available via open access

Lessons from the HEALEY Adaptive Platform Trial in Amyotrophic Lateral Sclerosis


First published: 01 November 2024

Pending Open Access



<https://www.nature.com/articles/s43587-024-00740-x>

Regimen-specific papers in the works:



Reporting the results of the first-ever platform trial for ALS

Read Q&A article:



<https://bit.ly/3D1wZjC>

In 2018, Sean Healey, a successful businessman, was diagnosed with ALS and began care under Cudkowicz. His story is inspiring. He recognized the inefficiencies in clinical trials and aimed to expedite the development of new treatments, wanting to leave a legacy in ALS research.

[He made a transformative donation](#), establishing the Healey Center and the HEALEY ALS platform trial—one of the center's signature projects.

In 2020, we launched the platform trial to accelerate drug discovery in ALS, aiming to decrease the time needed to develop treatments while minimizing the expense and the number of participants in placebo groups.

This trial has been a strong collaborative effort between academia, industry, and the patient and scientific communities. By working together, we hope to advance ALS research and foster innovative treatments.


Paper Cited

Paganoni, S., Harkey, B., Giacomelli, E., Cudkowicz, M., & HEALEY ALS Platform Trial Study Group (2024). Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis. *Nature aging*, 4(11), 1512–1515. <https://doi.org/10.1038/s43587-024-00740-x>

Navigating Clinical Trial Opportunities



- **ClinicalTrials.gov** – clinicaltrials.gov/

-  **ALS TDI Trial Navigator** – www.als.net/als-trial-navigator/

- **ALS Signal (I AM ALS)** – www.iamals.org/get-help/als-signal-clinical-research-dashboard/
- **NEALS** – neals.org/als-trials/neals-affiliated
- **MDA** – www.mda.org/research/clinical-trials
- **ALSA** – www.als.org/research/finding-als-research-opportunities
- **International Alliance of ALS/MND Associations** – www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/


Educational Webinar Opportunities



Visit the NEALS website
to explore upcoming webinars or
view previous recordings




<https://bit.ly/3S4P0Sb>



December 18, 2024 / 12:00 pm–1:00 pm

Examining Psilocybin for Existential Distress in People with ALS

People with ALS can experience emotional distress and mood-related issues such as depression, a decline in quality of life, and feelings of hopelessness and helplessness, known as existential distress. There are few therapies that...



December 11, 2024 / 1:00 pm–2:00 pm

The Role of AI in ALS

Advanced methods of machine learning have paved the way for a new generation of medical and clinical research. New methods and data resources can offer better diagnostics, new therapeutics, and disease management. Conditions such as ALS...

A NOTE ABOUT RECORDINGS: LINKS TO THE RECORDINGS OF ALL PRESENTATIONS AND SPEAKERS ARE LOCATED UNDER EACH TALK TITLE IN THE AGENDA'S BELOW. <https://www.alsonerresearchsymposium.org/>



Monepantel (NUZ-001)
Active Substance, Pharmacological Class, History

Name: Monepantel (NUZ-001)
CAS No.: 887148-69-8

Pharmacological Class: mTOR inhibitor

Chemical Name
N-[(2S)-1-Cyano-2-(5-cyano-2-trifluoromethyl-phenoxy)-1-methyl-ethyl]-4-(trifluoromethylsulfonyl)-benzamide

Structural Formula
(S)-monepantel enantiomer is used in the Drug Product for treatment of ALS

History
Monepantel (NUZ-001) was previously developed as the veterinary drug (Zovivir®), and has been approved since 2009 in Australia, New Zealand, and 36 other countries as an oral broad spectrum anthelmintic for the treatment of gastrointestinal roundworms in sheep. Mode of action as a de-worming agent is sheep-specific.

Neurizon

2:37 / 26:06



Neurizon Therapeutics (formerly PharmAust)

Title: Exploring the Benefits of mTOR Inhibition in Patients with Amyotrophic Lateral Sclerosis.

Speaker: Dr Michael Thurn, Managing Director

<https://www.youtube.com/watch?v=wkqKoJ4DZ4Y>

Patient Navigation

Central resource for people living with ALS

Two webinars
per month



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu

ALS Link sign-up:



<https://bit.ly/3CqGbhb>

Weekly webinar
registration:



<https://bit.ly/3r6Nd2L>

Upcoming Webinars (Thurs, 5:00- 5:30pm EST):

January 9th- Monthly Expanded Access Update

January 23rd- Platform Trial Update



Allison Bulat